Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Releases List To Encourage Competition

Executive Summary

China's National Health Commission issues list of 34 generic drugs that have 'insufficient' competition, seeking public comments.

You may also be interested in...



China Dodges Chance To Impose Linkage And Exclusivity

Patent-linkage and data exclusivity changes have not been implemented in a major overhaul of medicines law in China. But they could still come through patent law updates.

Cipla Docks Into China With Manufacturing Plans In Tow

More Indian companies are headed to China, with Cipla the latest to seal a joint venture there, though the firm has previous links with the country. Respiratory products will lead Cipla’s line-up in China, a market seen as a crucial cog in the firm’s future road map.

Alembic Charts China Plans, Sees Price Cuts As No Dampener

Alembic has firmed up a joint venture to tap into emerging opportunities in China amid evolving regulations there, and believes the market holds significant promise despite rising price pressures.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel